Anocca Doses First Patients with KRAS-Targeted TCR-T Therapy
SÖDERTÄLJE, Sweden, June 11, 2026 Anocca AB announced the successful dosing of the first patients in its VIDAR-1 clinical...
Pancreatic Cancer
Advertisement
Oncolytics Reports Promising Pelareorep Data in RAS Cancers
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Advertisements
PanTher Advances PTM-101 Into Expansion Phase for Non-Metastatic Pancreatic Cancer
AUSTIN, Texas | May 30, 2026 PanTher Therapeutics announced the completion of the dose-escalation portion of its Phase 1b...
Phanes Advances Spevatamig with Encouraging PDAC Data
SAN DIEGO, May 28, 2026 Phanes Therapeutics announced updated positive Phase 2 clinical trial results for spevatamig (PT886) in...
Oncolytics’ Pelareorep Shows Strong KRAS-Targeted Immune Activation at ASCO 2026
SAN DIEGO, May 22, 2026 Oncolytics Biotech® announced new translational data from its GOBLET and AWARE-1 studies showing that...
ClearNote Health to Present Strong ASCO 2026 Data for Avantect Pancreatic Cancer Blood Test
SAN DIEGO, May 22, 2026 ClearNote Health announced that it will present new multi-cohort validation data for its Avantect®...
Valion Bio Advances Entolimod for Radiation Emergencies
SAN ANTONIO, Texas, May 19, 2026 Valion Bio, Inc. has announced a high-level joint engagement with senior officials from...
Advertisement
